Amelioration of diabetic nephropathy by orange peel extract in rats

Natural Product Research

Volumn 28, Issue 23, 2014, Pages 2178-2181

  Parkar, Nishad ^a,b   Addepalli, Veeranjaneyulu ^b  

^a SVKM S DR BHANUBEN NANAVATI COLLEGE OF PHARMACY   (India)

^b Narsee Monjee Institute of Management Studies   (India)

Author keywords

diabetic nephropathy; extracellular matrix; orange peel extract

Indexed keywords

CREATININE; FLAVONOID; GELATINASE A; GELATINASE B; GLUCOSE; SOUR ORANGE EXTRACT; STREPTOZOCIN; UREA; NITROGEN; PHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG SCREENING; ENZYME ACTIVITY; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOLOGY; KIDNEY; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY HYPERTROPHY; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; SOUR ORANGE; TUBULOINTERSTITIAL FIBROSIS INDEX; UREA NITROGEN BLOOD LEVEL; URINARY TRACT DISEASE ASSESSMENT; ANIMAL; BLOOD; CHEMISTRY; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; ISOLATION AND PURIFICATION; MALE; PATHOLOGY; SWEET ORANGE;

ANIMALS; CITRUS SINENSIS; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FLAVONOIDS; KIDNEY; MALE; NITROGEN; PHENOLS; RATS; UREA;

EID: 84908574233     PISSN: 14786419     EISSN: 14786427     Source Type: Journal    
DOI: 10.1080/14786419.2014.925894     Document Type: Article

References (10)

1. Cooper ME. 1998. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 352: 213-219.
2. Furness PN. 1997. Basement membrane synthesis and degradation. J Pathol. 183: 1-3.
3. Giunti S, Barit D, Cooper ME. 2006. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension. 48: 519-526.
4. He X-G, Lian L-Z, Lin L-Z, Bernart MW. 1997. High-performance liquid chromatography-electrospray mass spectrometry in phytochemical analysis of sour orange (Citrus aurantium L). J Chromatogr A. 791: 127-134.
5. Hiroshi O, Akira N, Kentaro M, Ryong-Woon S, Koichi O, Daisuke S, Naomi T, Akihito Y, Yutaka S, Yoshihiro M., et al. 2008. Nobiletin, a citrus flavonoid, improves memory impairment and Aβ-pathology in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 326: 739-744.
6. Nagase H, Woessner JF. 1999. Matrix metalloproteinases. J Biol Chem. 274: 21491-21494.
7. Sato T, Koike L, Miyata Y, Hirata M, Mimaki Y, Sashida Y, Yano M, Ito A. 2002. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 Cells. Cancer Res. 62: 1025-1029.
8. Sato T, Takahashi A, Kojima M, Akimoto N, Yano M, Ito A. 2007. A citrus polymethoxy flavonoid, nobiletin inhibits sebum production and sebocyte proliferation, and augments sebum excretion in hamsters. J Invest Dermatol. 127: 2740-2748.
9. Yanji C, Jinji W, Sung-Cherl J, Deok-Bae P, Young-Hee M, Jeong YH, Se-Jae K, Sun-Ryung L, Soon-Jong K, Sang Jeong K, Su-Yong E. 2010. Antineuroinflammatory activity of nobiletin on suppression of microglial activation. Biol Pharm Bull. 33: 1814-1821.
10. Young-Sil L, Byung-Yoon C, Kiyoto S, Hiroshi Y, Sun-Sil C, Kohji Y, Takayuki Y, Toshiaki T, Kazuo N, Je-Tae W. 2010. Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem Pharmacol. 79: 1674-1683.